These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19781947)

  • 21. N-(4-Substituted-benzoyl)-N'-(β-d-glucopyranosyl)ureas as inhibitors of glycogen phosphorylase: Synthesis and evaluation by kinetic, crystallographic, and molecular modelling methods.
    Nagy V; Felföldi N; Kónya B; Praly JP; Docsa T; Gergely P; Chrysina ED; Tiraidis C; Kosmopoulou MN; Alexacou KM; Konstantakaki M; Leonidas DD; Zographos SE; Oikonomakos NG; Kozmon S; Tvaroška I; Somsák L
    Bioorg Med Chem; 2012 Mar; 20(5):1801-16. PubMed ID: 22325154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
    Oikonomakos NG; Tiraidis C; Leonidas DD; Zographos SE; Kristiansen M; Jessen CU; Nørskov-Lauritsen L; Agius L
    J Med Chem; 2006 Sep; 49(19):5687-701. PubMed ID: 16970395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarbo xylate.
    Oikonomakos NG; Tsitsanou KE; Zographos SE; Skamnaki VT; Goldmann S; Bischoff H
    Protein Sci; 1999 Oct; 8(10):1930-45. PubMed ID: 10548038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The σ-hole phenomenon of halogen atoms forms the structural basis of the strong inhibitory potency of C5 halogen substituted glucopyranosyl nucleosides towards glycogen phosphorylase b.
    Kantsadi AL; Hayes JM; Manta S; Skamnaki VT; Kiritsis C; Psarra AM; Koutsogiannis Z; Dimopoulou A; Theofanous S; Nikoleousakos N; Zoumpoulakis P; Kontou M; Papadopoulos G; Zographos SE; Komiotis D; Leonidas DD
    ChemMedChem; 2012 Apr; 7(4):722-32. PubMed ID: 22267166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A New Potent Inhibitor of Glycogen Phosphorylase Reveals the Basicity of the Catalytic Site.
    Mamais M; Degli Esposti A; Kouloumoundra V; Gustavsson T; Monti F; Venturini A; Chrysina ED; Markovitsi D; Gimisis T
    Chemistry; 2017 Jul; 23(37):8800-8805. PubMed ID: 28493496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory mode of indole-2-carboxamide derivatives against HLGPa: molecular docking and 3D-QSAR analyses.
    Liu G; Zhang Z; Luo X; Shen J; Liu H; Shen X; Chen K; Jiang H
    Bioorg Med Chem; 2004 Aug; 12(15):4147-57. PubMed ID: 15246091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New synthesis of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles, nanomolar inhibitors of glycogen phosphorylase.
    Kun S; Bokor É; Varga G; Szőcs B; Páhi A; Czifrák K; Tóth M; Juhász L; Docsa T; Gergely P; Somsák L
    Eur J Med Chem; 2014 Apr; 76():567-79. PubMed ID: 24608000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New pentacyclic triterpenes from Gypsophila oldhamiana and their biological evaluation as glycogen phosphorylase inhibitors.
    Luo JG; Liu J; Kong LY
    Chem Biodivers; 2008 May; 5(5):751-7. PubMed ID: 18493961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW; Rath VL; Genereux PE; Hageman DL; Levy CB; McClure LD; McCoid SC; McPherson RK; Schelhorn TM; Wilder DE; Zavadoski WJ; Gibbs EM; Treadway JL
    Bioorg Med Chem Lett; 2005 Jan; 15(2):459-65. PubMed ID: 15603973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissecting the catalytic mechanism of a plant beta-D-glucan glucohydrolase through structural biology using inhibitors and substrate analogues.
    Hrmova M; Fincher GB
    Carbohydr Res; 2007 Sep; 342(12-13):1613-23. PubMed ID: 17548065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FlexE: efficient molecular docking considering protein structure variations.
    Claussen H; Buning C; Rarey M; Lengauer T
    J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies.
    Wen X; Sun H; Liu J; Cheng K; Zhang P; Zhang L; Hao J; Zhang L; Ni P; Zographos SE; Leonidas DD; Alexacou KM; Gimisis T; Hayes JM; Oikonomakos NG
    J Med Chem; 2008 Jun; 51(12):3540-54. PubMed ID: 18517260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance.
    Perola E; Walters WP; Charifson PS
    Proteins; 2004 Aug; 56(2):235-49. PubMed ID: 15211508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases.
    Fernández D; Avilés FX; Vendrell J
    Eur J Med Chem; 2009 Aug; 44(8):3266-71. PubMed ID: 19386397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystallographic studies on N-azidoacetyl-beta-D-glucopyranosylamine, an inhibitor of glycogen phosphorylase: comparison with N-acetyl-beta-D-glucopyranosylamine.
    Petsalakis EI; Chrysina ED; Tiraidis C; Hadjiloi T; Leonidas DD; Oikonomakos NG; Aich U; Varghese B; Loganathan D
    Bioorg Med Chem; 2006 Aug; 14(15):5316-24. PubMed ID: 16616506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition.
    Goyard D; Kónya B; Czifrák K; Larini P; Demontrond F; Leroy J; Balzarin S; Tournier M; Tousch D; Petit P; Duret C; Maurel P; Docsa T; Gergely P; Somsák L; Praly JP; Azay-Milhau J; Vidal S
    Org Biomol Chem; 2020 Feb; 18(5):931-940. PubMed ID: 31922157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of docking programs for predicting binding of Golgi alpha-mannosidase II inhibitors: a comparison with crystallography.
    Englebienne P; Fiaux H; Kuntz DA; Corbeil CR; Gerber-Lemaire S; Rose DR; Moitessier N
    Proteins; 2007 Oct; 69(1):160-76. PubMed ID: 17557336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative structure-based design: formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase.
    Pan D; Tseng Y; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(5):1591-607. PubMed ID: 14502494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core.
    Rath VL; Ammirati M; LeMotte PK; Fennell KF; Mansour MN; Danley DE; Hynes TR; Schulte GK; Wasilko DJ; Pandit J
    Mol Cell; 2000 Jul; 6(1):139-48. PubMed ID: 10949035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.